QCM Cayman’s Pfizer PFE Stock Holding History

QCM Cayman’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-9,501	Closed	-$264K	–	48
2024 Q1	$264K	Buy	+9,501	New	+$264K	3.55%	13
2023 Q4	–	Sell	-6,491	Closed	-$215K	–	44
2023 Q3	$215K	Buy	+6,491	New	+$230K	1.4%	39
2021 Q4	–	Sell	-5,545	Closed	-$238K	–	118
2021 Q3	$238K	Sell	5,545 -1,331	-19%	-$59K	0.65%	69
2021 Q2	$269K	Buy	+6,876	New	+$267K	0.7%	56
2018 Q2	–	Sell	-13,216	Closed	-$445K	–	150
2018 Q1	$445K	Buy	+13,216	New	+$454K	1.15%	22
2017 Q2	–	Sell	-10,449	Closed	-$339K	–	355
2017 Q1	$339K	Buy	+10,449	New	+$329K	0.06%	247
2016 Q3	–	Sell	-9,064	Closed	-$303K	–	313
2016 Q2	$303K	Buy	+9,064	New	+$289K	0.13%	125
2015 Q2	–	Sell	-16,362	Closed	-$540K	–	235
2015 Q1	$540K	Buy	+16,362	New	+$520K	0.29%	53

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

QCM Cayman's PFE Position: Q2 2024 in Review

QCM Cayman sold out of Pfizer (PFE) in Q2 2024, closing a stake of 9,501 shares — an estimated $264K sold.

QCM Cayman first reported a position in PFE in Q1 2015 and held it in 8 quarters. The position peaked at $540K in Q1 2015. 2,874 funds tracked by Wall St. Rank hold PFE as of Q2 2024.

QCM Cayman reported no remaining Pfizer position as of Q2 2024 after selling out during the quarter.
QCM Cayman sold 9,501 Pfizer shares in Q2 2024, an estimated $264K.
QCM Cayman first reported a position in Pfizer in Q1 2015 and held it in 8 quarters.
QCM Cayman's Pfizer position peaked at $540K in Q1 2015.
2,874 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.

Based on QCM Cayman's 13F filing for Q2 2024, filed 14 Aug 2024.